c-MET (D1228N)

MET · Variant type: point · HGVS: p.D1228N

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Cabozantinib	93.9%	6.1%	92.73
2	Crizotinib	92.8%	7.2%	91.39
3	Gilteritinib	90.1%	9.9%	88.97
4	Pacritinib	64.2%	35.8%	88.64
5	Tivozanib	61.8%	38.2%	92.42
6	Defactinib	58.9%	41.1%	92.68
7	Repotrectinib	56.3%	43.7%	84.21
8	Fostamatinib	47.0%	53.0%	96.74
9	Neratinib	42.7%	57.3%	93.18
10	Axitinib	36.3%	63.7%	93.23
11	Lenvatinib	32.8%	67.2%	97.74
12	Vemurafenib	31.0%	69.0%	96.49
13	Selpercatinib	30.4%	69.6%	96.72
14	Sunitinib	26.4%	73.6%	91.73
15	Afatinib	25.2%	74.8%	98.50
16	Brigatinib	22.5%	77.5%	82.96
17	Entrectinib	20.5%	79.5%	93.69
18	Tepotinib	20.5%	79.5%	99.75
19	Fedratinib	19.9%	80.1%	96.21
20	Abemaciclib	17.5%	82.5%	91.48
21	Dabrafenib	16.1%	83.9%	94.74
22	Capmatinib	15.9%	84.1%	99.75
23	Canertinib	15.1%	84.9%	96.49
24	Sorafenib	12.8%	87.2%	96.72
25	Ponatinib	12.4%	87.6%	78.23

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Cabozantinib	93.9%	—	—
Crizotinib	92.8%	—	—
Gilteritinib	90.1%	—	—
Pacritinib	64.2%	—	—
Tivozanib	61.8%	—	—
Defactinib	58.9%	—	—
Repotrectinib	56.3%	—	—
Fostamatinib	47.0%	—	—
Neratinib	42.7%	—	—
Axitinib	36.3%	—	—
Lenvatinib	32.8%	—	—
Vemurafenib	31.0%	—	—
Selpercatinib	30.4%	—	—
Sunitinib	26.4%	—	—
Afatinib	25.2%	—	—
Brigatinib	22.5%	—	—
Entrectinib	20.5%	—	—
Tepotinib	20.5%	—	—
Fedratinib	19.9%	—	—
Abemaciclib	17.5%	—	—
Dabrafenib	16.1%	—	—
Capmatinib	15.9%	—	—
Canertinib	15.1%	—	—
Sorafenib	12.8%	—	—
Ponatinib	12.4%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.0ms